VRX Could be Worth 30% More If It Can Continue to Execute For those of you that quit on Valeant Pharmaceuticals International Inc. (VRX) , such as hedge funder Bill Ackman who dumped his stake in March, you may want to reconsider your stance on the stock.
That's at least according to one Wall Street that firm that hiked its price target on the biopharma company about 28% in an evening note on Wednesday.
Cantor Fitzgerald & Co. analyst Louise Chen has raised her price target on Valeant Pharmaceuticals Intl Inc. (VRX) to $23 from $18, citing multiple expansion opportunities.
"We think this is deserved because Valeant's execution has continued to meet or exceed our expectations," Chen wrote in a Wednesday, June 28, note.